Login to Your Account

Pharma: Clinic Roundup

Wednesday, April 17, 2013
• Eli Lilly and Co., of Indianapolis, reported top-line data showing that the primary efficacy endpoints of noninferiority of dulaglutide, a long-acting glucagon-like peptide 1 receptor agonist, to insulin glargine, as measured by the reduction of hemoglobin A1c levels, were met in two studies, AWARD-2 and AWARD-4.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription